NLRP3 and metabolic dysfunction-associated steatotic liver disease: In a murine model of NAFLD, silymarin suppresses NLRP3 inflammasome activation via the nicotinamide adenine dinucleotide (NAD+)/SIRT2 pathway (Zhang B. et al., 2018).